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NOTES
HOW MUCH REGULATION CAN WE SWALLOW?
THE BAN ON EPHEDRA AND HOW IT MAY AFFECT
YOUR ACCESS TO DIETARY SUPPLEMENTS
Reilley Michelle Dunne*
I. INTRODUCTION
Steve Bechler, a pitcher for the Baltimore Orioles, was young, healthy, and active,
and on February 17, 2003, while running sprints, he suddenly collapsed. 1  The
paramedics attending the team's practice session examined Bechler, and after his
condition did not improve, they took him to the hospital in an ambulance, giving
Bechler oxygen and fluids the entire way.
2 He died the next day.3
After Bechler collapsed, a member of the team staff took a bottle out of Bechler's
locker and threw it in the trash.4  The bottle was a dietary supplement containing
ephedrine, a stimulant designed to minimize fatigue, control weight, and enhance
athletic performance. 5 The doctors concluded that Bechler died from multiple organ
failure caused by heatstroke and that ephedrine contributed to his death, making Bechler
the second player in baseball history to have died as a direct result of on-field activity.
6
Bechler is not the first professional athlete whose death was linked to ephedrine. In
August 2001, Minnesota Vikings offensive lineman Korey Stringer died from
complications of heat stroke, and several bottles of supplements containing ephedrine
were found in his locker.7 In addition, eleven football players at various levels died in
training in 2001, including Northwestern University defensive back Rashidi Wheeler
and Florida State University's Devaughn Darling.8 Many other consumers who were
* J.D. Candidate, Notre Dame Law School, 2005; B.A. University of Oregon, 2001. The author would like to
thank her parents and brother for their love and support and for always encouraging her to embrace new
challenges.
1. Duff Durkin, Stricken Oriole had Ephedrine, Sources Claim, WASH. TIMES, Feb. 17, 2003, at C 1.
2. Id.
3. Duff Durkin, Orioles Pitcher Dies of Heatstroke; Bechler Said to Have Been Taking Supplement
Ephedrine, WASH. TIMES, Feb. 18, 2003, at AO1.
4. Durkin, supra note 1.
5. Id.
6. The other player in organized baseball who died as a direct result of on-field activity was Cleveland
Indians shortstop Ray Chapman, who was hit in the head by a pitch from the New York Yankees' Carl Mays
during a game in 1920. Peter Schmuck, Ephedrine Banned by NFL, not MLB, CHI. TRIB., Feb. 18, 2003, at 4.
7. Durkin, supra note 1, at C 1.
8. Id.
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not high caliber athletes have also died after taking supplements containing ephedrine.
For example, Anne Marie Capati, a 37-year-old mother of two children, took several
supplements recommended by her "trainer-nutritionist" and died from intracranial
bleeding due to elevated blood pressure.9 These incidents were serious enough that the
National Football League ("NFL"), various high school federations, and other athletic
organizations reviewed their drug policies, and several enacted bans against using any
supplements containing ephedrine. 10 Baseball was slow to react, however, and did not
ban the use of ephedra; Steve Bechler suffered as a result.
Despite the fact that the Federal Drug Administration ("FDA") has reported nearly
150 deaths and has received almost 16,000 adverse event reports due to the use of
ephedra, its use was not banned until the FDA and the Department of Health and
Human Services ("HHS") issued a consumer alert notifying all manufacturers that the
sale of products containing ephedrine alkaloids would be banned. 12 Although the action
to ban ephedra was long overdue, the consequences of this ban are not yet realized.
A potential consequence is that, because the FDA and HHS banned the sale of
products containing ephedra, the agencies will also ban the sale of other dietary
supplements. Although banning ephedra is an appropriate step that the FDA is justified
in taking in order to protect consumers from the dangers that ephedra poses, the
government should not overstep its boundaries by banning other less harmful dietary
supplements. The ban on ephedra should be a special case, limited only to products
containing ephedra or ephedrine-alkaloids, and should not extend to other dietary
supplements.
This Note examines the FDA's ban on ephedra and the potential effects that the ban
may have on the dietary supplement industry and on consumers. Part II discusses the
history of the FDA's authority to regulate food and drug products in the United States
and the current law regulating dietary supplements. Part III explains the special dangers
that ephedra presents and shows the strong reaction that federal and state governments,
as well as consumers generally, have had to the harsh effects of ephedra. Finally, in
Part IV, the Note examines other dietary supplements available on the market and
concludes that, while the FDA was justified in banning ephedra, the FDA should not
ban other dietary supplements simply because they may pose some threats to consumer
health. The Note suggests that, although the current law regulating the dietary
supplement industry is adequate, the FDA needs more funds to fully enforce the law.
Furthermore, the FDA must make increased efforts to educate consumers about the
benefits and dangers of using dietary supplements.
9. Paul D. Rheingold, Herbal Supplements May be Dangerous: Supplements May Look Like Magic
Bullets for Health Problems, but Users May be Playing Russian Roulette, TRIAL 42, 42 (Nov. 1999).
10. Schmuck, supra note 6, at 4.
11. Consumers who wish to file complaints about food products, including dietary supplements, can
complete a form and submit it to the FDA. Forms are available at http://www.fda.gov/medwatch/report/
consumer/consumer.htm. See also discussion infra Part II.B.
12. Press Release, U.S. Dep't of Health and Human Serv., FDA Announces Plans to Prohibit Sales of
Dietary Supplements Containing Ephedra (Dec. 30, 2003), available at http://www.hhs.gov/news/press/
2003pres/20031230.html (last visited Mar. 15, 2005) [hereinafter, Press Release, FDA Announces Plans to
Prohibit Sales].
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II. THE DEREGULATION OF THE DIETARY SUPPLEMENT MARKET
According to HHS, approximately 60% of Americans take some form of dietary
supplement, including vitamins, minerals, and other herbal remedies, daily without any
adverse effects. 13 Yet dietary supplements, also known as herbal supplements or herbal
remedies, may be extremely dangerous when taken with other substances or alone in
excessive amounts, and therefore they must be regulated just as other drug and food
products are regulated. However, unlike other food and drug products, the FDA is not
the main regulatory body that oversees the production, advertising, and manufacturing
of dietary supplements. The removal of the FDA from the forefront of regulating
dietary supplements has been the subject of most of the controversy surrounding the
current regulatory scheme of dietary supplements. Although the law currently
regulating dietary supplements has several downfalls, 14 dietary supplements continue to
be necessary and desired by consumers. Therefore, the law should not be drastically
amended simply because one dietary supplement, ephedra, has been found to present
unreasonable risks to consumers.
A. Progression to the Current Deregulatory Scheme
Until 1994, the FDA was largely responsible for controlling dietary supplements in
the United States. The FDA regulated herbal supplements under the Federal Food,
Drug, and Cosmetic Act ("FDCA"), 15 under which the FDA could classify dietary
supplements as drugs or food additives. 16 For example, under the FDCA, the FDA
could classify a dietary supplement as a drug based on the manufacturer's intended use
for the supplement.17 Under either classification, the supplement had to receive FDA
approval prior to any marketing of the supplement. 
18
However, supplements were most commonly classified as food additives, and,
under the 1958 Food Additive Amendment to the FDCA,19 the FDA received authority
to regulate dietary supplements as food additives. 20 This meant that the FDA could
evaluate the safety of all new ingredients, which ensured that the supplements available
to the public were safe and labeled accurately. 21 As a result of this amendment, the
FDA directed more attention to studying the dangers of dietary supplements, and in the
1960s, the FDA spent more money trying to regulate this industry than any other area.
22
In the 1970s, the FDA focused its regulation of herbal supplements by prohibiting
13. DEP'T OF HEALTH & HUMAN SERV., OFFICE OF THE INSPECTOR GEN., ADVERSE EVENT REPORTING
FOR DIETARY SUPPLEMENTS: AN INADEQUATE SAFETY VALVE 1 (Apr. 2001), at http://oig.hhs.gov/oei/
reports/oei-01-00-00180.pdf (last visited Mar. 15, 2005).
14. See discussion infra Part lI.B.
15. 21 U.S.C. § 301 (1994).
16. Stephanie Kauflin, Comment, Dietary Supplements: Is Availability Worth the Risks? Proposed
Alternatives to the Present DSHEA Scheme, 33 SETON HALL L. REV. 411, 412 (2003).
17. lona N. Kaiser, Dietary Supplements: Can the Law Control the Hype, 37 HOUS. L. REV. 1249, 1252
(2000).
18. Id.
19. 21 U.S.C. § 321(s) (1994).
20. Kaiser, supra note 17, at 1252-53.
21. Id.
22. Id. at 1252.
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"irrational combinations '23 and dosages of vitamins and minerals, which the Second
Circuit validated as falling within the FDA's regulatory authority.
24
In response to outraged consumers and herbal supplement manufacturers, Congress
revoked this power by enacting the Proxmire Amendment, 25 which retracted the FDA's
authority to regulate dietary supplements based on irrational combinations or levels of
potency. 26 Furthermore, in National Nutritional Foods Association v. Mathews,27 the
Second Circuit held that the FDA must justify its classification of a nutrient contained
in a dietary supplement as a drug by analyzing the public's use of and need for the
supplement, 28 which strengthened the effect of the Proxmire Amendment and
effectively stripped the FDA of its regulatory power over herbal supplements.
29
As a result of the Proxmire Amendment, the FDA scaled back its efforts to regulate
dietary supplements, and the market for herbal supplements expanded by the 1990s.
30
However, in the summer and fall of 1989, the amino acid supplement L-tryptophan was
linked to 1,500 adverse effects, including thirty-eight deaths, and the FDA renewed its
efforts to protect the public from dietary supplements with increased aggressiveness. 31
For example, when Congress enacted the Nutrition Labeling and Education Act of
1990, 32 which requires labeling of foods and prohibits manufacturers from making
unsupported health claims about their products, the FDA required that the same
standards apply to dietary supplements. 33 Congress reacted by enacting the Dietary
Supplement Act of 1992, 34 which stopped the FDA from applying these standards to
herbal supplements. However, the FDA continued its efforts to limit the availability of
dietary supplements to consumers.
35
The FDA's renewed proactive course for regulating dietary supplements prompted
dietary supplement manufacturers to organize a "National Blackout Day" in which
dietary supplement retailers draped black cloths over the supplement bottles that would
potentially be affected by the FDA's increased regulation in an effort to convince
23. Irrational combinations are those "provid[ing] quantitative combinations or nutrients for which no
human individual need could possibly exist, if the products are used only as dietary supplements."
Definitions and Standards of Identity for Food and Special Dietary Uses, 38 Fed. Reg. 20,730, 20,738 (Aug.
2, 1973).
24. Nat'l Nutrition Foods Ass'n v. FDA, 504 F.2d 761, 774, 786 (2d Cir. 1974) (expressing the court's
favorable impression of the FDA's effort to more strictly regulate dietary supplements, but disallowing the
FDA to completely block the sale of any dietary supplement whose nutritional value is unclear).
25. 21 U.S.C. § 350(a) (1994).
26. Id.
27. 557 F.2d 325 (2d Cir. 1977)
28. Id. at 337-38.
29. Margaret Gilhooley, Herbal Remedies and Dietary Supplements: The Boundaries of Drug Claims
and Freedom of Choice, 49 FLA. L. REV. 665, 675 (1997).
30. Id. at 676.
31. Kaiser, supra note 17, at 1255.
32. Nutrition Labeling and Education Act, Pub. L. No. 101-535, 104 Stat. 2353 (1990) (codified as
amended at 21 U.S.C. § 343).
33. Trisha L. Beckstead, Caveat Emptor, Buyer Beware: Deregulation of Dietary Supplements upon
Enactment of the Dietary Supplement Health and Education Act of 1994, 11 SAN JOAQUIN AGRIC. L. REV.
107,111 (2001).
34. Dietary Supplement Act of 1992, Pub. L. No. 102-571, Title II, 106 Stat. 4491, 4500 (1992) (codified
as amended in scattered sections of2l U.S.C.).
35. See generally Beckstead, supra note 33, at I11.
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consumers that the FDA was trying to destroy consumer access to supplements. 36 The
movement worked. As a response to significant pressure from the public and dietary
supplement manufacturers, Congress passed the Dietary Supplement Health and
Education Act of 1994 ("DSHEA"), 37 which created an entirely new regulatory scheme
for dietary supplements.
38
B. Congress's Current Legislation. The DSHEA
The DSHEA represents Congress's attempt to balance consumer access to dietary
supplements and the regulation necessary to ensure product safety.39 Congress intended
the DSHEA to benefit consumers who wanted access to herbal supplements that could
remedy their ailments as alternatives to prescription drugs. 40  Congress realized that
consumers believed that dietary supplements could improve their health, and so it
passed the DSHEA to empower consumers "to make choices about preventative health
care programs based on data from scientific studies of health benefits related to
particular dietary supplements. ' 4 1  Congress further found that "the importance of
nutrition and the benefits of dietary supplements to health promotion and disease
prevention have been documented increasingly in scientific studies" and that "dietary
supplements are safe within a broad range of intake, and safety problems with the
supplements are relatively rare. ' '42  Therefore, Congress determined that "legislative
action that protects the right of access of consumers to safe dietary supplements is
necessary in order to promote wellness .... ,43
The DSHEA has changed the regulation of dietary supplements in several
significant ways. Prior to the DSHEA, the term "dietary supplement" was defined as a
vitamin or mineral,44 but the DSHEA redefined dietary supplement as "a product [for
ingestion] intended to supplement the diet." 45 Any product that meets the definition
outlined in the DSHEA is now classified as a dietary supplement and is exempt from
classification as a food additive.46 This classification prevents the FDA from requiring
dietary supplement manufacturers, unlike food additive manufacturers, to meet
premarket approval standards for safety.47 Therefore, if a manufacturer introduces a
product into the market and classifies it as a dietary supplement, the product does not
need to meet any additional safety requirements. The DSHEA does not require
scientific evidence showing that the product is reasonably safe for public consumption
36. Kaiser, supra note 17, at 1258.
37. Dietary Supplement Health and Education Act of 1994, Pub. L. No. 103-417, 108 Stat. 4325 (1994)
(codified in scattered sections of 21 U.S.C.) [hereinafter Dietary Supplement Health and Education Act].
38. Int'l Ass'n of Def. Counsel, Conning the IADC Newsletters, 69 DEF. COUNS. J. 517, 519 (2002).
39. Lauren J. Sloane, Herbal Garden of Good and Evil: The Ongoing Struggles of Dietary Supplement
Regulation, 51 ADMIN L. REV. 323, 327 (1999).
40. See Beckstead, supra note 33, at 112; see also Sloane, supra note 39, at 332-33.
41. Dietary Supplement Health and Education Act § 2(8).
42. Id. § 2(14).
43. Id. § 2(15)(A).
44. Beckstead, supra note 33, at 109.
45. Dietary Supplement Health and Education Act § 3 (codified in 21 U.S.C.A. § 321(ff)).
46. Id. § 3(b) (codified in 21 U.S.C.A. § 321(s)(6)).
47. Cary Elizabeth Zuk, Note, Herbal Remedies are Not Dietary Supplements: A Proposal for
Regulatory Reform, 11 HASTINGS WOMEN'S L.J. 29, 38-39 (2000).
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but instead presumes that the dietary supplement is safe.48  Manufacturers are not
required to submit safety and efficacy reports to the FDA for prior approval, and dietary
supplements may enter the market without standardized dosages or strengths.
49
Although the United States is one of the few industrialized nations that does not
require premarket approval of dietary supplements, the DSHEA does include some
premarket safety provisions. First, under the DSHEA, if a manufacturer proposes to
make a claim that the supplement can mitigate, treat, cure, or prevent a disease, the
manufacturer must notify the FDA that the supplement's label contains such a claim
within thirty days after first marketing the supplement. 5 1 Second, the DSHEA extends
the FDA's rule on current good manufacturing practices ("cGMP"), which previously
only applied to food products, to apply to dietary supplements as well.52 Although the
FDA has not finalized the publication of a dietary supplement cGMP rule, which was
initially proposed on March 13, 2003, the rule will likely create standards for how
dietary supplements are prepared, packaged, and stored, and is intended to help prevent
the inclusion of wrong ingredients in dietary supplements and of contaminants in the
supplement bottles.5 3 Third, the DSHEA provides specific requirements for premarket
notification to the FDA of any new dietary ingredients, which are defined as ingredients
that were sold on the market in the United States after October 15, 1994. 54  The
manufacturer must show evidence that the new dietary ingredient can "reasonably be
expected to be safe," 55 and the FDA may prohibit any marketing of the product if the
FDA finds the evidence unsatisfactory. 56 In addition, the FDA may take action and
conclude that the supplement presents a risk to public safety if the dietary supplement or
an ingredient in the supplement is adulterated, 57 which means that the dietary
supplement or ingredient "presents a significant or unreasonable risk of illness or
injury" under conditions of use recommended in the labeling or under ordinary
conditions of use.
58
Despite these provisions, the FDA faces many challenges in being able to
implement the protective provisions contained within the DSHEA. Most dietary
supplements are not subject to any premarket approval and may appear on the shelves,
available to consumers, without FDA approval. Furthermore, the DSHEA shifts the
burden of ensuring the safety of the product from the dietary supplement manufacturer
to the FDA to show that the product is unsafe.59 To do this, the FDA primarily relies on
48. See Beckstead, supra note 33, at 109.
49. Jennifer Sardina, Note, Misconceptions and Misleading Information Prevail-Less Regulation Does
Not Mean Less Danger to Consumers: Dangerous Herbal Weight Loss Products, 14 J.L. & HEALTH 107, 114
(1999-2000).
50. ROWENA K. RICHTER, HERBAL MEDICINE: CHAOS IN THE MARKETPLACE 121-22 (2003).
51. Dietary Supplement Health and Education Act § 6 (codified in 21 U.S.C.A. § 343(q)(5)(F)).
52. Id. § 9 (codified in 21 U.S.C.A. § 342(g)(1)).
53. Ctr. for Food Safety and Applied Nutrition, U.S. Food and Drug Admin., Fact Sheet on FDA 's
Strategy for Dietary Supplements, (Nov. 4, 2004), at http://www.cfsan.fda.gov/-dms/ds3strfs.html (last
visited Mar. 15, 2005).
54. Dietary Supplement Health and Education Act § 8 (codified in 21 U.S.C.A. § 350b(a)).
55. Id. (codified in 21 U.S.C.A. § 350b(a)(2)).
56. Id. § 4 (codified in 21 U.S.C.A. § 342(f)).
57. Id. (codified in 21 U.S.C.A. § 342).
58. Id.
59. Id. (stating "the United States shall bear the burden of proof on each element to show that a dietary
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the Adverse Event Reporting System developed by the FDA's Center for Food Safety
Applied Nutrition ("CFSAN"), 6° under which consumers can notify the FDA that they
have experienced a harmful effect or illness from consuming a dietary supplement.
61
However, because the reporting of adverse events is not mandatory, the system in its
current form is ineffective at alerting the FDA to the dangers of some dietary
supplements, such as ephedra, as the FDA is slow to respond to the reports it receives.
Furthermore, the reporting only occurs after consumers have experienced adverse
reactions to the dietary supplement,62 which does nothing to alleviate the pain of those
consumers who experienced the reactions.
The FDA must build a strong case in order to remove the product from the market,
which often takes years and requires the development of strong scientific evidence and
a large collection of adverse event reports showing that the product is dangerous to
consumers. 63 Consequently, the FDA will commonly issue public warnings rather than
attempt to declare that a dietary supplement is adulterated. 64 However, these warnings
usually do not result in the removal of the product from the retail market, and
consumers may still have access to the unsafe dietary supplements, such as ephedra.
65
III. EPHEDRA: A DANGEROUS DIETARY SUPPLEMENT THAT PRESENTS A SPECIAL CASE
FOR THE FDA AND HHS
Many dietary supplements sold in drug stores, pharmacies, and supermarkets
contain ephedrine and related alkaloids as their primary ingredients. 66 Because ephedra
is a dietary supplement, it is regulated under the DSHEA. As the most controversial
dietary supplement on the market, ephedra arrived at the forefront of the debate
surrounding the pitfalls of the DSHEA. However, because it has received such national
attention and led to numerous deaths of young, healthy people, 67 it is a unique dietary
supplement, and the FDA and HHS should treat it as such. We must examine the
special qualities and circumstances involving ephedra in order to understand what
makes ephedra different from other dietary supplements and determine why it should
therefore be banned while others should not.
supplement is adulterated").
60. See Dietary Supplement Safety Act: How is FDA Doing 10 Years Later? Hearing Before Comm. on
Senate Gov't Affairs, Subcomm. on Oversight of Gov't Mgmt., 108th Cong. (2004) (statement of Robert
Brackett, Ph.D., Director for Ctr. for Food Safety and Applied Nutrition of the U.S. Food and Drug Admin.),
available at http://hsgac.senate.gov/index.cfin?Fuseaction=Hearings.Testimony&HearinglD=179&WitnesslD
=647&IsTextOnly=O (last visited Mar. 15, 2005).
61. Ctr. for Food Safety and Applied Nutrition, U.S. Food and Drug Admin., Adverse Event Reporting,
at http://www.cfsan.fda.gov/-dms/ds-rept.html (last visited Mar. 15, 2005).
62. See id. ("If you think that you have suffered a serious harmful side effect or illness from a dietary
supplement, your health care provider can report this by [using the Adverse Event Reporting System].").
63. Int'l Ass'n of Def. Counsel, supra note 38, at 520.
64. Id.
65. Id.
66. /d. at 517.
67. See discussion infra Part 1.
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A. Characteristics, Functions, and Uses of Ephedra
Ephedra is a chemical compound naturally occurring in the Chinese herb ma
huang, which was originally used as a decongestant for colds, asthma, and hay fever.
68
Ephedrine, which is the active ingredient in ephedra, is a compound that boosts
metabolism and consequently burns calories. 69 Ephedrine also acts as adrenaline in the
human body.70  It excites the nervous system, opens the blood vessels, and then
stimulates the heart.
71
Dietary supplement manufacturers have capitalized on this function of the herb by
including it in many weight loss dietary supplements, claiming that ephedrine will bum
fat while maintaining muscle tissue.72 Many athletes-from the high school to the
professional levels-have used ephedra to improve their appearance or athletic
performance, hoping that it will help them reduce their fat weight relative to their
muscle weight.
73
Unfortunately, serious problems arise when the product is taken in incorrect
dosages, which is not uncommon and extremely dangerous. 74 Ephedrine has several
side effects, none of which are life-threatening on their own: "nervousness, headaches,
insomnia, dizziness, palpitations, skin flushing, tingling, and vomiting." 75 However, if
the consumer takes too much ephedrine--exceeding the amount suggested on the
label-the herb can cause serious injuries and even death.76 Also, ephedrine takes six
to ten hours to metabolize in the body, and therefore, if the consumer repeatedly takes
the supplement, the substance can build to toxic levels in the body.77 Furthermore, the
combination of ephedrine with caffeine-containing products, such as coffee, chocolate,
or over-the-counter pain relievers, can amplify ephedra's effects and can further
increase the risks associated with the herb.
78
Manufacturers of dietary supplements containing ephedra have experienced the
backlash that can result from consumption of supplements containing ephedra. For
example, Metabolife International, Inc. ("Metabolife"), 79 a manufacturer of dietary
supplements and nutritional herbs, markets its products as aids for weight management,
wellness, and health maintenance. One of Metabolife's products, Metabolife 356,
contains ephedrine alkaloids, and after several individuals suffered adverse reactions
68. Zuk, supra note 47, at 43.
69. Id.
70. Jeffrey A. Crossman, Comment, Mark McGwire Does It, So Why Can't I? High School Student Use
of Dietary Supplements and the Failure of DSHEA, 28 CAP. U. L. REV. 617, 634 (2000).
71. Id. at 634.
72. Id.; see discussion infra.
73. Crossman, supra note 70, at 634.
74. Id.
75. Id. (quoting Tod L. Stewart, Getting High with a Little Help from the Feds: Federal Regulation of
Herbal Stimulants, 6 J. PHARMACY & L. 101, 103 (1997)).
76. Id.
77. Sardina, supra note 49, at 118.
78. Id. at 118-19.
79. Metabolife is a California corporation that sells dietary supplements promoting weight loss, including
Metabolife 356, which contains ephedrine alkaloids. Appellant's Opening Brief at 4-5, Scott v. Metabolife
Int'l, Inc., 9 Cal. Rptr. 3d 242 (2004) (No. C041029).
80. Id. at 4-5.
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after taking Metabolife 356, Metabolife found itself defending several lawsuits. 81 Class
action lawsuits asserted strict products liability claims against Metabolife for marketing
unsafe products, as well as claims of false advertising and consumer fraud. 82  The
pending litigation 83 has added to the media attention, spurring a debate concerning the
safety of ephedra, ephedrine alkaloids, and dietary supplements in general.
B. The Fight Against Ephedra
Despite the political power of dietary supplement manufacturers, those supporting
the ban on ephedra have created a national debate surrounding the substance. Ephedra
has received most of the attention from those challenging the effectiveness of the
DSHEA, most likely due to the deaths of high profile athletes such as Bechler, Stringer,
Wheeler, and Darling, and the fact that the FDA ultimately banned the supplement.
84
1. Federal Action against Ephedra
The FDA's early recognition of the dangers of ephedra and ephedrine-containing
dietary supplements led to the FDA's long-term efforts to discourage consumers from
purchasing and using the supplement. 85 Beginning as early as September 1994, the year
that the DSHEA was passed, the FDA issued a "Medical Bulletin," alerting consumers
that it had received many adverse event reports associated with ephedrine-containing
dietary supplements for weight loss, energy, performance-enhancing, and body-building
purposes. 86 The FDA continued this fight against ephedra in 1997 by holding several
hearings to discuss the substance, and subsequently proposed several regulations for
labeling ephedrine alkaloids, such as advising against using more than eight milligrams
"per serving" or twenty-four milligrams daily of ephedrine, and warning against use
during pregnancy or in the presence of other health conditions.
87
The FDA modified this proposed rule in 2000,88 and on February 28, 2003, HHS
and the FDA issued a press release, announcing a series of actions designed to protect
Americans from the potentially serious risks of ephedra. 89 The announcement followed
81. See, e.g., Scott, 9 Cal. Rptr. 3d at 244-45; Kemp v. Metabolife Int'l, Inc., No. Civ.A.00-3513, 2003
WL 22326560, at *1 (E.D. La. Oct. 7, 2003).
82. Scott, 115 Cal. App. 4th at 408; Kemp, 2003 WL 22326560, at *1.
83. In Kemp, the District Court in Louisiana granted summary judgment motions in favor of Metabolife,
stating that the plaintiffs failed to prove through medical testimony that Metabolife is the "actual cause" of the
injuries the plaintiffs suffered. Kemp v. Metabolife Int'l, Inc., No. 00-3513, 2004 WL 2095618, at *4, *6
(E.D. La. Sept. 13, 2004). This ruling shows the challenges that plaintiffs asserting claims against dietary
supplement manufacturers will face, as proving causation for injuries sustained from taking dietary
supplements is difficult.
84. See discussion supra Part I.
85. See Int'l Ass'n of Def. Counsel, supra note 38, at 520.
86. Id.
87. Rheingold, supra note 9, at 43.
88. Press Release, FDA Announces Plans to Prohibit Sales, supra note 12.
89. Press Release, U.S. Food and Drug Admin., HHS Acts to Reduce Potential Risks of Dietary
Supplements Containing Ephedra (Feb. 28, 2003), available at http://www.fda.gov/bbs/
topicsINEWS/2003/NEW00875.htm (last visited Mar. 15, 2005) [hereinafter Press Release, HHS Acts to
Reduce Potential Risks]. As part of those actions, HHS and FDA pledged to do the following: (1) seek
public comment on the new evidence of health risks associated with ephedra; (2) seek public comment on
2005]
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the release of numerous studies that found that ephedra may be associated with
important health risks while showing only limited health benefits. 90  This
announcement included publishing a Federal Register notice reopening a comment
period so that consumers could voice their own opinions on the FDA's proposed
regulation from 1997 and 2000.
91
In conjunction with the FDA's efforts to make consumers more aware of the
dangers of ephedra, certain members of Congress focused their attention on the dangers
of ephedra, particularly following the death of Steve Bechler. Senators John McCain
(R-AZ) and Fritz Hollings (D-SC) were primarily responsible for spurring this
movement in Congress to ban, or at least increase the regulation of, ephedra.
In March 2003, the Senate Committee on Commerce, Science, and Transportation,
of which Sen. McCain is Chairman and Sen. Hollings is Ranking Member, wrote to the
Secretary of HHS, Tommy G. Thompson, encouraging him to expand his agency's
review of ephedra and other "potentially-dangerous dietary supplements. ' 92  The
Committee further stated that HHS's "ongoing effort to assess the potential health risks
of ephedra and to help educate the American public about the product is clearly
necessary and overdue." 93  This committee was primarily responsible for the
government's push to ban ephedra until the FDA and HHS took action against the
dietary supplement in December 2003.
94
2. States and Private Organizations React Against the Use of Ephedra
Several states initially took a more proactive approach than the federal government
toward achieving increased regulation and a ban against ephedrine-containing products.
In May 2003, Illinois Governor Rod R. Blagojevich signed legislation that made Illinois
the first state in the country to ban the sale of ephedra. 95 In signing the bill, Blagojevich
stated, "With enough commitment, this ban can sweep through state legislatures across
America and sweep this product right off the shelf."
96
Several states followed Illinois's lead in banning or restricting consumer access to
products containing ephedrine alkaloids. New York banned the sale of dietary
supplements containing ephedra by amending the state's general business law in August
whether currently available evidence shows a "significant or unreasonable risk of illness or injury" from
dietary supplements containing ephedra; (3) seek comment on a strong new warning label on any ephedra
products that continue to be marketed; and (4) execute a series of actions against ephedra products making
unsubstantiated claims about sports performance enhancement. Id.
90. Id.
91. Id.
92. Letter from John S. McCain, Chairman, Senate Committee on Commerce, Science, and
Transportation, and Ernest F. Hollings, Ranking Member, Senate Committee on Commerce, Science, and
Transportation, to Honorable Tommy G. Thompson, Secretary, U.S. Department of Health and Human
Services (Mar. 20, 2003), available at http://www.commerce.senate.gov/pdf/ephedraletter032003.doc (last
visited Mar. 15, 2005).
93. Id.
94. See discussion infra Part III.C.
95. 720 ILL. COMP. STAT. ANN. 602/10 (2003); see also Press Release, Office of the Governor of Illinois,
Blagojevich Signs Legislation Banning Sale of Ephedra (May 25, 2003), at http://www.illinois.gov/
PressReleases/PressReleasesListShow.cfm?RecNum=2137 (last visited Feb. 7, 2005) [hereinafter Press
Release, Blagojevich Signs Legislation].
96. Press Release, Blagojevich Signs Legislation, supra note 95.
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2003.97  In California, the sale or distribution of any dietary supplement product
containing ephedrine alkaloids is now prohibited unless the product label clearly and
conspicuously contains a statement warning consumers that the product has a specified
amount of ephedrine alkaloid.98 Florida also makes it unlawful to distribute weight-loss
pills that contain ephedra or ephedrine alkaloids to any person less than eighteen years
of age.
9 9
Private organizations have also banned the use of ephedra because of the serious
health risks associated with it. For example, the National Collegiate Athletic
Association ("NCAA") and the International Olympic Committee ("IOC") have banned
products containing ephedra or ephedrine alkaloids. 100 In September 2001, following
the death of Korey Stringer, 10 ' the NFL banned ephedra, becoming the first professional
sports organization to do so. 10 2 Under the NFL ban, players are prohibited from taking,
distributing, having, and even endorsing ephedra and companies that manufacture
products containing ephedrine alkaloids. 
103
C. FDA and HHS Announce Ban of Ephedra
On December 30, 2003, the FDA and HHS announced the agencies' intent to ban
• 104
the sale of these dietary supplements. On February 11, 2004, the FDA issued its final
regulation prohibiting the sale of dietary supplements containing ephedrine alkaloids,
effective April 12, 2004, declaring "dietary supplements containing ephedrine alkaloids
are adulterated under the [FDCA] because they present an unreasonable risk of illness
or injury .... 105 Sixty-two companies received the letter from the FDA announcing
the intended ban on their products. 1
06
This ban on ephedra was the FDA's first ban on any dietary supplement. 10 7 FDA
Commissioner Mark B. McClellan stated that the purpose of their action was to "notify
Americans about the unreasonable risk of ephedra as currently marketed in dietary
supplements" and was based on "diligent and thorough work by the agency . . . [to]
review all the available evidence about the risks and benefits of ephedra, including its
97. 2003 N.Y. LAW 385.
98. CAL. HEALTH & SAFETY CODE § 110423 (2003).
99. FLA. STAT. ANN. § 501.0583 (2003).
100. Int'l Ass'n of Def. Counsel, supra note 38, at 518.
101. See discussion supra Part I.
102. Id.
103. Int'l Ass'n of Def. Counsel, supra note 38, at 518.
104. Press Release, FDA Announces Plans to Prohibit Sales, supra note 12.
105. Final Rule Declaring Dietary Supplements Containing Ephedrine Alkaloids Adulterated Because
They Present an Unreasonable Risk, 69 F.R. 6788, 6788 (Feb. 11, 2004); see also 21 C.F.R. § 119.1 (2005);
Press Release, U.S. Food and Drug Admin., FDA Issues Regulation Prohibiting Sale of Dietary Supplements
Containing Ephedrine Alkaloids and Reiterates its Advice that Consumers Stop Using These Products (Feb. 6,
2004), available at http://www.fda.gov/bbs/topics/NEWS/2004/NEW0102l.html (last visited Feb. 7, 2004)
[hereinafter FDA Issues Regulation].
106. To view a list of all the companies that were notified of this ban, see U.S. FDA, Companies
Marketing Ephedra Dietary Supplements that Received FDA's Letter Dec. 30, 2003, at
http://www.fda.gov/oc/initiatives/ephedra/december2003/letterslist.html (last visited Mar. 15, 2005).
107. Anna Wilde Mathews & Stefan Fatsis, Ban on Ephedra Sets a Bar for Tougher Regulations, WALL
ST. J., Dec. 31, 2003, at D2.
2005]
Journal of Legislation
pharmacology, studies of ephedra's safety and effectiveness, adverse event reports, and
reviews by independent experts."'
10 8
At the time, the FDA's evaluation of ephedra reflected the available studies,
reviewed by the RAND Corporation, 10 9 which "found little effectiveness other than for
short-term weight loss" of ephedra, yet also suggested serious safety risks.110  As
mentioned previously, those risks include increased blood pressure and other stresses to
the circulatory system, which have been "conclusively linked to significant and
substantial adverse health effects like heart problems and strokes."' 11
Despite the studies and evidence supporting the FDA's ruling that ephedra
presented an unreasonable risk to consumer safety, on April 13, 2005, a federal district
court in Utah found that the FDA violated the DSHEA when it issued the ban on
ephedra. 12  In Neutraceutical Corp. v. Crawford, several manufacturers of dietary
supplements containing low-doses of ephedrine-alkaloid 1 3 challenged the validity of
the FDA's ban on ephedra, arguing that the rule violates the DSHEA. 14 Specifically,
the plaintiffs argued that the FDA did not establish that ephedra was adulterated
because it presented a "significant or unreasonable risk of illness or injury" as required
under the DSHEA. 1 5 The court granted the plaintiffs' motion for summary judgment,
finding that the FDA improperly applied a risk-benefit analysis in determining that
ephedrine-alkaloids are adulterated. 16 The court held that, in enacting the DSHEA,
Congress did not intend for dietary supplements to be required to demonstrate a benefit
to health, and thus the FDA should not have weighed the benefits of ephedra against the
risks associated with the dietary supplement." 7 Furthermore, the court found that the
evidence upon which the FDA based its ban was insufficient to show that the low-dose
of ephedrine-alkaloids in this case presented an unreasonable risk to consumers." 8 The
court remanded the decision to the FDA and enjoined the FDA from enforcing the ban
on the sale of dietary supplements containing ten milligrams or less of ephedrine-
alkaloids per daily dose.'l 9
This district court ruling raises questions as to whether the FDA's ban on ephedra
will remain intact. To date, the FDA has not responded to the decision, and so the
consequences of this ruling are yet unknown. Despite this new development, ephedra
has presented significant-and devastating-risks to consumer health, 20 and therefore
the ban was appropriate.
108. Press Release, FDA Announces Plans to Prohibit Sales, supra note 12.
109. The RAND Corporation is a nonprofit organization that conducts research in areas such as business,
education health law, and science. See http://www.rand.org/about/ (last visited Mar. 15, 2005).
110. Press Release, FDA Announces Plans to Prohibit Sales, supra note 12.
111. Id.
112. Neutraceutical Corp. v. Crawford, No. 2:04-CV-408-TC, 2005 WL 852157, at *10 (D. Utah Apr. 13,
2005).
113. The recommended dose of the dietary supplements in this case yielded less than ten milligrams of
ephedrine-alkaloids per day, which is considered a low-dose. Id. at *1.
114. Id. at *5.
115. Id. at *3, 5; see also 21 U.S.C. § 342(f).
116. Id. at *8.
117. Id. at *8.
118. Neutraceutical Corp., 2005 WL 852157 at *10.
119. Id. at *10.
120. See discussion supra Parts 1, III.A; see also discussion infra Part.IV.
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IV. THE BAN ON EPHEDRA SHOULD NOT LEAD TO A CRUSADE TO BAN OTHER DIETARY
SUPPLEMENTS
While the FDA's and HHS's response to the dangers that ephedra presented to
public safety was necessary and long overdue, the agencies should not use this action as
a springboard for banning other dietary supplements. Ephedra was a special case; it
was a unique dietary supplement that led consumers to question the effectiveness of
dietary supplements in general. According to a study published in 2003 in the Annals of
Internal Medicine, ephedra is associated with greater risks for adverse effects than other
commonly used herbal products. 12 Although products containing ephedra make up
less than 1% of all dietary supplement sales, these products account for 64% of adverse
events associated with dietary supplements. 122  Furthermore, the study found that
relative risks for adverse effects from ephedra were 100 times greater than from Kava
and as much as 700 times greater than from Ginko Biloba, two other common herbal
remedies.123 Although ephedra had negative consequences, a multitude of other dietary
supplements are not harmful and should not be banned.
Simply because ephedra poses serious threats to public health and safety, the FDA
and HHS should not embark on a crusade to ban more dietary supplements. Ephedra
received extensive media coverage, which is evident by the fact that the NFL, NCAA,
and IOC banned the substance, and the U.S. Senate created a special committee to
address concerns regarding the supplement. Aside from the 2004 controversy
surrounding androstenedione, 124 no other dietary supplement has received as much
attention and public outcry as ephedra. In fact, not one state has attempted to ban other
herbs, such as Echinacea or St. John's wort, even though some consumers have
experienced adverse reactions to both. 125  The FDA and HHS took appropriate
measures to ban ephedra, but the ban should stop there. Dietary supplements provide
valuable benefits to the public, and the FDA should not interfere with consumers' rights
to access these affordable remedies.
A. The Case ofAndrostenedione: The FDA's First Action Against the Dietary
Supplement Industry Following the Ban on Ephedra
A few months following the ban on ephedra, HHS and the FDA announced a
"crackdown" on dietary supplements containing another natural ingredient,
androstenedione ("andro"). 126  Primarily used by athletes to enhance athletic
performance, stimulate muscle growth, and increase production of testosterone, andro
121. Stephen Bent et al., The Relative Safety of Ephedra Compared with Other Herbal Products, 138
ANNALS OF INTERNAL MED. 468, 470 (2003), at http://www.annals.org/cgi/content/full/138/6/468 (last visited
Mar. 15, 2005).
122. Id. at 469.
123. Id.
124. See discussion infra Part IV.A.
125. See discussion infra Part IV.B.
126. Press Release, U.S. Dep't of Health and Human Serv., HHS Launches Crackdown on Products
Containing Andro: FDA Warns Manufacturers to Stop Distributing Such Products (Mar. 11, 2004), available
at http://www.fda.gov/bbs/topics/news/2004/hhs_031104.html (last visited Mar. 15, 2005) [hereinafter HHS
Launches Crackdown].
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acts like a steroid once it is metabolized by the body and therefore can pose health risks
similar to those associated with illegal steroids. 127  Examples of such long-term
consequences in men are testicular atrophy, impotence, and the development of female
characteristics, such as breast enlargement. 128 In women, the potential consequences
are baldness, deepening of the voice, increased facial hair, abnormal menstrual cycles,
and increased risk of breast cancer and endometrial cancer. 129 Children who use andro
are at risk for early onset of puberty and of premature cessation of bone growth.13
0
Although HHS and the FDA did not completely ban products containing andro, the
FDA sent warning letters to twenty-three companies asking them to stop distributing
products sold as dietary supplements that contain andro and warning them that they
could face "enforcement actions" if the companies do not take "appropriate actions."
' 13 1
Although the end-result for products containing andro essentially parallels the end-
result for products containing ephedra-both are effectively removed from consumer
access-the means that the FDA used to reach the conclusion differs. The FDA banned
ephedra following the collection of several years of data and adverse event reports
indicating the dangers of ephedra. 132  The basis for the FDA action against
manufacturers of andro, on the other hand, lies in the definition of "dietary ingredient"
and the requirement for premarket approval for new dietary ingredients in the
DSHEA. 133 In the warning letter, the FDA stated that it assumed that andro is a dietary
ingredient, and therefore, because the FDA believes that andro is also a new dietary
ingredient, premarket safety notification is required. 134 Because no manufacturer or
distributor of andro products has submitted such notification, the products are
adulterated and therefore cannot be marketed under the FDCA.
135
The problem with this analysis is that the FDA has broadened its authority to
regulate dietary supplements, overreaching the powers granted to the agency to regulate
dietary supplements in the DSHEA. Under this framework, the FDA is able to simply
assume that any ingredient in any dietary supplement is a new dietary ingredient,
thereby requiring the manufacturers of the product containing the ingredient to submit
premarket notifications to the FDA, which may then make it more expensive and
difficult for manufacturers to offer dietary supplements to consumers. Although a total
ban on andro may be a justifiable action to protect consumers against the harmful
effects of andro, the method that the FDA used to achieve this regulation may be
troublesome to manufacturers of other safe dietary supplements and to consumers using
those supplements.1
36
127. Id.
128. Id.
129. [d.
130. Id.
131. Id. The actions that the FDA warned it would take to non-complying manufacturers include "seizing
violative product[s] as well as pursuing injunctions or seeking criminal sanction against persons who violate
the law." HHS Launches Crackdown, supra note 126.
132. See discussion supra Part III.
133. Id.; see also discussion supra Part I.B.
134. Press Release, HHS Launches Crackdown, supra note 126.
135. Id.
136. Congress is currently considering a bill, the Anabolic Steroid Control Act of 2004, which would
prohibit the sale of certain steroid hormone precurors, like andro, by adding them to the list of controlled
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B. Public Health Benefits of Other Dietary Supplements
Many cultures have used herbal remedies for thousands of years, and consumers
should continue to have access to these types of alternative medicines. Consumers
prefer using herbal supplements instead of prescriptive medicines for several reasons:
(1) herbal remedies are less expensive; (2) herbal supplements are easier to purchase;
and (3) dietary supplements "offer a sense of control to consumers 'who are suspicious
of the medical establishment. ' 13 7 Ephedra is merely one type of herbal remedy that
consumers have used, but there are many others that provide important health benefits
as alternatives to pharmaceuticals. While some herbal remedies have adverse side
effects, the public health benefits that the herbs provide are great enough that they
should remain available to the public.
For example, many consumers have used St. John's wort to treat depression,
insomnia, and anxiety. 13 8 In fact, in Germany, doctors commonly prescribe products
made from St. John's wort for the treatment of depression instead of prescribing other
pharmaceuticals. 39  In the United States, St. John's wort was the fifth most popular
herbal remedy purchased in 1997, 140 and between 1995 and 1998, demand for the herb
increased from 500 tons per year to 6,000 tons. 141 Although demand for St. John's wort
has decreased in the last few years, the herbal remedy offers a more cost-effective
treatment for depression than other pharmaceutical anti-depressants and might have
fewer side effects for consumers.142
However, the FDA and other research organizations have questioned the safety and
effectiveness of St. John's wort, despite the fact that the herb has undergone rigorous
testing in Germany. 143 For example, in February 2000, the National Institute of Health
("NIH") and the National Center for Complementary and Alternative Medicine
("NCAAM") conducted a study and found an adverse effect resulting from the
interaction between St. John's wort and indinavir, commonly known as Crixivan, which
is a protease inhibitor used to treat HIV.144 This spurred the FDA to issue a public
substances, a proposition that has not (yet) been suggested for other products classified as dietary
supplements. See S. 2195, 108th Cong. § 2 (2004); see also David Seckman, Second Session: Update on
Dietary Supplement Legislation, 66 BETTER NUTRITION 48 (2004), available at 2004 WL 55134663 (last
viewed Mar. 15, 2005). This bill, sponsored by Sens. Joe Biden (D-DE) and Hatch (R-IA), further signifies
the difference between the regulation of dietary supplements and products like andro, supporting the argument
that the FDA's actions regarding the regulation of andro should not become the model for the FDA's
treatment of other dietary supplements.
137. Sloane, supra note 39, at 331-32 (citation omitted).
138. Id. at 333-34; but see Nat'l Ctr for Complementary and Alternative Med., St. John's Wort and the
Treatment of Depression, at http://nccam.nih.gov/health/stjohnswort/index.htm (last visited Mar. 15, 2005)
(stating that recent studies suggest that St. John's wort is not beneficial in treating major depression of
moderate severity).
139. RICHTER, supra note 50, at 103.
140. Id. (citing Peggy Brevoort, The Booming US. Botanical Market: A New Overview, HERBALGRAM 44,
33-46 (1998)).
141. Id. (citing Manuel Collado Campos, Address at the American Herbal Products Association's
International Symposium on St. John's Wort, Anaheim, Cal. (Mar. 16-17, 1998)).
142. Id. at 104.
143. Id. at 104-05.
144. Nat'l Ctr. for Complementary and Alternative Med., St. John's Wort and the Treatment of
Depression 4, at http://nccam.nih.gov/health/stjohnswort/index.htm (last visited Mar. 15, 2005).
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health advisory warning to consumers about these dangers of using St. John's wort even
though the warnings would affect only a relatively small percentage of consumers.
145
The mere fact that St. John's wort may cause some adverse effects when combined with
other drugs should not prevent consumers from using it. Germany, along with many
other European countries, and Australia have recognized the positive effects of the
herbal remedy for many years, and Americans should have access to it as an alternative
to other drugs.
Other herbal remedies have provided consumers with treatment for various
ailments. For example, Echinacea, a treatment for the common cold, and Kava Kava,
which promotes relaxation and relieves tension, stress, and anxiety, have provided
consumers with a range of health benefits. 146 In addition, a recent study published in
the Archives of Neurology found that the combination of taking vitamins E and C
reduced the incidence of Alzheimer's disease by about 64 percent. 147 The herb Ginkgo
Biloba has also been helpful in treating Alzheimer's. 148 Consumers have recently
turned to dehydroepiandrosterone ("DHEA") to "hinder or stop the aging process,
combat depression and cancer, increase memory, and strengthen the immune
system."' 149 Taking a simple stroll down the aisle of any local grocery store, pharmacy,
or natural foods store reveals hundreds of varieties of herbal remedies, including
products containing herbs such as Ginseng and Echinacea, that provide consumers with
cheap alternatives to pharmaceuticals.
C. The FDA's Initiatives to Further Implement the DSHEA
As a step toward improving its ability to identify harmful effects in dietary
supplements, in April 2004, the FDA sponsored a study, conducted by the National
Council of the National Academies and the Institute of Medicine ("IOM"), to offer
science-based processes and guidelines for evaluating the safety of dietary
supplements. 150  The report described the various scientific assessments that can be
used to identify supplement ingredients that may pose risks, categorized different kinds
of data that the FDA can use to assess safety, and offered guidelines for determining the
significance of the evidence available on a particular substance.
151
Furthermore, following the ban on ephedra, the FDA demonstrated its efforts to
further implement the DSHEA by announcing three major regulatory initiatives
designed to achieve this goal. 152 In the first initiative, a regulatory strategy, the FDA
145. Press Release, U.S. Food and Drug Admin., Public Health Advisory: Risk of Drug Interactions with
St. John's Wort and Indinavir and Other Drugs (Feb. 10, 2000), available at http://www.fda.gov/cder/
dmg/advisory/stjwort.htm (last visited Apr. 2, 2005).
146. See RICHTER, supra note 50, at 109; see also Zuk, supra note 47, at 50.
147. Peter P. Zandi et. al, Reduced Risk of Alzheimer Disease in Users of Antioxidant Vitamin
Supplements: The Cache County Study, 61 ARCH. NEUROL. 82 (2004), available at http://archneur.ama-
assn.org/cgi/content/abstract/61/1/82 (last visited Apr. 2, 2005).
148. RICHTER, supra note 50, at 108.
149. Sloane, supra note 39, at 335.
150. Press Release, Nat'l Academies, Report Offers Science-Based Process and Guidelines to Evaluate
Safety of Dietary Supplements (Apr. 1, 2004), available at http://www4.nationalacademies.org/
news.nsf/isbn/0309091 101?OpenDocument (last visited Apr. 2, 2005).
151. Id.
152. Press Release, U.S. Food and Drug Admin., FDA Announces Major Initiatives for Dietary
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pledged to work with organizations such as NIH, the Office of Dietary Supplements
("ODS"), and NCAAM to improve the process by which the FDA makes safety and
enforcement decisions about the regulation of dietary ingredients and dietary
supplements. 153  Specifically, the FDA vowed to pay closer attention to "signal
detections," or signals of possible safety concerns originating from federal and state
agencies, adverse event reports, media reports, information from consumer groups, and
consultations with experts.
154
The FDA's second initiative was to hold a public meeting in November 2004,
designed to "seek public comment on the type, quantity, and quality of evidence
manufacturers should provide [the] FDA in a new dietary ingredient notification."
155
As its third initiative, the FDA asked for comments from leaders in the dietary
supplement industry on a "draft guidance document on the amount, type, and quality of
evidence a manufacturer should have to substantiate a claim" arising under the FDCA,
which would help establish a clearer standard for substantiation and thus may help
preserve consumer confidence in dietary supplements.
156
While the issuing of these initiatives represents the FDA's commitment to fully
implement the DSHEA, the actual benefits derived from these initiatives is left unseen.
Because many of the actions promised in the initiatives have yet to occur-aside from
the public meeting-we cannot be certain whether the initiatives will lead to increased
regulation of dietary supplements. From the strategies outlined in the press releases and
announcements, however, the FDA appears to be taking the right steps by pledging to
improve its evaluation process for responding to adverse event reports, by gathering
scientific data on dietary supplements, and by consulting consumers and industry
leaders about the manufacturing requirements for dietary supplements. As long as the
initiatives do not lead to the adoption of the proposals suggested by IOM,157 such as
regulating dietary supplements as drugs are regulated, the initiatives are the appropriate
responses to help ensure consumers have continued access to safe dietary supplements.
D. Subsequent Efforts to Ban More Dietary Supplements
Despite the well-documented public health benefits that dietary supplements
provide to consumers, several public leaders and consumer organizations are currently
advocating for legislation that would more heavily regulate dietary supplements and
Supplements (Nov. 4, 2004), available at http://www.fda.gov/bbs/topics/news/2004/NEW01130.html (last
visited Feb. 1, 2005) [hereinafter Press Release, FDA Announces Major Initiatives for Dietary Supplements].
153. Id.
154. Id.
155. Id.; see also Dep't Health and Human Serv., Public Health Serv., U.S. Food and Drug Admin.,
Dietary Supplements; Premarket Notification for New Dietary Ingredient Notifications; Public Meeting, 69
Fed. Reg. 61,680-03 (Oct. 20, 2004). The FDA did, in fact, hold this public meeting, which consisted of
presentations from a variety of experts, including David Seckman, Executive Director and CEO of National
Nutritional Foods Association, Annette Dickinson, Ph.D., President of the Council for Responsible Nutrition,
and Michael McGuffin, President of American Herbal Products Association. Transcript, Dep't Health and
Human Serv., Public Health Serv., U.S. Food and Drug Admin., Ctr. for Food Safety and Applied Nutrition,
Dietary Supplements Public Meeting Pre-Market Notification Program for New Dietary Ingredients, at
http://www.fda.gov/ohrms/dockets/dockets/04nO454/04n-0454-trOOOOl.htm (last visited Feb. 9, 2005).
156. Press Release, FDA Announces Major Initiatives for Dietary Supplements, supra note 152.
157. See discussion infra Part IV.D.3.
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would subsequently decrease consumer access to herbal remedies. For example,
organizations such as Consumers Union 158 argue that the ban on ephedra does not go
far enough to protect consumers from potentially dangerous supplements. 159 Charles
Bell, the program director for Consumers Union, called ephedra the "poster child for a
failed policy," and urged the federal government to give the FDA more authority to
regulate all dietary supplements. 160  In addition, several members of Congress
recognize that consumers are interested in the issues involving dietary supplements and
have proposed solutions to the problem of how to ensure that consumers are not
exposed to unsafe products.
1. Proposed Legislation: The Dietary Supplement Safety Act of 2003
In March 2003, Sen. Dick Durbin (D-Ill.) introduced a bill, the Dietary Supplement
Safety Act of 2003 ("Dietary Supplement Safety Act"), which intended to amend the
FDCA to "require that manufacturers of dietary supplements submit to the [FDA]
reports on adverse experiences with dietary supplements ... ,,161 The bill, which is co-
sponsored by Senators Hillary Clinton (D-N.Y.), Dianne Feinstein (D-Calif.), John
McCain, (R-Ariz.), and Charles Schumer (D-N.Y.), would also eliminate a provision of
the FDCA that requires the FDA to bear the burden of proof to show that the dietary
supplement is adulterated due to a safety violation. 162 The bill creates new definitions,
such as "adverse dietary supplement experience,"' 163 and requires the manufacturer of
the dietary supplement to conduct extensive premarket and postmarket analyses of their
products. 164
The Dietary Supplement Safety Act would also prohibit the delivery of any dietary
supplement containing a stimulant into interstate commerce unless approved by the
government. 165 The bill defines "stimulant" as anything that has a "stimulant effect on
the cardiovascular system or the central nervous system," including anything that
speeds the metabolism, increases heart rate, constricts blood vessels, or causes the body
to release adrenaline. 166  According to this provision, products that are intended to
increase muscle hardness and other steroid precursors that are currently available could
no longer be marketed freely. 167 Sen. Durbin positioned his bill to address the dangers
158. Consumers Union is an independent, nonprofit testing and information organization that provides
"unbiased advice" about products and services, health and nutrition, and other consumer concerns. See
Consumers Union, About Consumers Union, at http://www.consumersunion.org/aboutcu/about.html (last
visited Feb. 7, 2005).
159. See Press Release, Consumers Union, Consumers Union Praises FDA Move to Ban Ephedra (Dec.
30, 2003), available at http://www.consumersunion.org/pub/core-productsafety/000721.html (last visited
Feb. 7, 2005) [hereinafter Press Release, Consumers Union].
160. Id.
161. S. 722, 108th Cong. (2003).
162. Id.
163. The term "adverse dietary supplement experience" means "an adverse event that is associated with
the use of a dietary supplement in a human, without regard to whether the event is known to be causally
related to the dietary supplement." Id. § 2.
164. Id.
165. Id. § 3.
166. Id. § 3(a).
167. See Dorsey Griffith, California Lawmakers Target Dietary Supplements, Steroids, Druglike Agents,
SACRAMENTO BEE, Jan. 1, 2004, at 24.
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that ephedra presents to consumers, as ephedra has been linked to several deaths, and he
therefore argues that all stimulant supplements must undergo a rigorous premarket FDA
approval process.168
This proposed legislation would drastically reduce consumer access to many
currently approved dietary supplements. 169  It would require dietary supplement
manufacturers to conduct incredibly expensive tests on all of their products, and if the
supplement failed any of the tests, the FDA would have full authority to remove it from
the market. 170  Project: Freedom of Access to Nutritional Supplements ("Project:
FANS"), a grassroots organization created to ensure that Americans have access to
dietary supplements, asserts that Sen. Durbin's legislation could potentially call for the
ban on vitamins used everyday by Americans, including calcium, vitamins E and C, and
even the Flintstones vitamins. 171  Sen. Orrin Hatch (R-Utah) reinforces that such a
result could occur: "[T]here are a number of current bureaucrats at the FDA who hate
dietary supplements and want to get pre-market approval, which would drive the costs
of [v]itamin C and other vitamins and minerals and even herbal products out of
sight."' 172 Sen. Durbin responded to these allegations by stating that his bill does not
require safety testing for vitamins, minerals, or the majority of dietary supplements, but
only for stimulants. 173 However, David Seckman, executive director of the National
Nutritional Foods Association ("NNFA"), criticizes Sen. Durbin's bill because it would
allow the FDA to make the manufacturer prove that a multivitamin is safe after only
one adverse reaction complaint, which will inevitably occur. 174 Seckman further argues
that when Congress addressed concerns regarding the dietary supplement industry, it
did not expect that "every time there is an issue with a supplement we [would] need
Congress to decide whether vitamin C or any other natural supplement should be
banned."
175
Another potential consequence of Sen. Durbin's bill is that many smaller
businesses producing dietary supplements would become insolvent. 176  The testing
168. See U.S. Senator John McCain (R-AZ) Holds a Hearing on Dangers of Dietary Supplements Before
Sen. Comm. on Commerce, Science & Transportation, Federal Document Clearing House, Inc., Political
Transcript (Oct. 28, 2003) (statement of Sen. Durbin) [hereinafter Statement of Sen. Durbin].
169. See Kelly Patricia O'Meara, Regulating Vitamins: Under Proposed Legislation Dressed Up as a
Public-Safety Concern, the Standard for Natural Dietary Supplements Would Be Set Far Above that for
Highly Profitable Drugs Being Pushed by Pharmaceutical Giants, INSIGHT ON THE NEWS, Sept. 16, 2003,
available at http://www.findarticles.com/p/articles/mi-ml571/is_2003-Sept-16/ai_107543542 (last visited
Apr. 2, 2005).
170. Id.
171. See Project: Fans, Comparison of Current Legislation, at http://www.projectfans.com/docs/S722.pdf
(last visited Feb. 6, 2004) [hereinafter Project: Fans, Comparison of Current Legislation]; see also Press
Release, Project: FANS, Senator Durbin Seeks Big Brother Government Regulation of "Dangerous"
Supplements, Y'know Like Flintstone Vitamins (July 22, 2003), available at http://www.projectfans.com/
docs/FlintstoneVitamins.pdf (last visited Feb. 7, 2005).
172. U.S. Senator John McCain (R-AZ) Holds a Hearing on Dangers of Dietary Supplements Before Sen.
Comm. on Commerce, Science & Transportation, Federal Document Clearing House, Inc., Political Transcript
(Oct. 28, 2003) (statement of Sen. Orrin Hatch) [hereinafter Statement of Sen. Hatch].
173. Sen. Dick Durbin, The Truth About the Dietary Supplement Act, INSIGHT ON THE NEWS, Dec. 8,
2003, available at http://www.findarticles.con/p/articles/mi-ml571/is_2003-Nov-24/ai 110364131 (last
visited Apr. 2, 2005).
174. O'Meara, supra note 169 (citation omitted).
175. Id.
176. See Project: FANS, Comparison of Current Legislation, supra note 171.
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requirements that the bill would impose upon all manufacturers of dietary supplements
would be too costly for small manufacturers to remain in business.177 The unavoidable
result would be that dietary supplements will no longer be affordable alternatives to
prescription drugs, which runs contrary to what Congress sought to ensure in passing
the DSHEA.178 If smaller manufacturers of dietary supplements become insolvent, they
will have to sell out to larger pharmaceutical companies, and inevitably, the price of
common herbal remedies, such as Echinacea, St. John's wort, and even vitamin C, will
increase. 
179
Another pitfall of Sen. Durbin's approach is that it assumes that the supplement
will no longer present any potential danger to consumers if the FDA approves the
dietary supplement. However, many drugs that the FDA approves do harm
consumers,180 despite the fact that the FDA has approved the drug before the drug
reaches the market. 18 1  For example, a common over-the-counter pain reliever is
responsible for more than 17,000 deaths annually, and prescription drugs are estimated
to be one of the top five leading contributors of deaths in the United States.
182
Additionally, the chemical stimulant methylphenidate, a drug that helps children with
the symptoms of attention deficit hyperactivity disorder ("ADHD"), has serious
potential side effects in children, such as decrease in bone growth, sleep disturbance,
increased blood pressure, tics, nausea, hypersensitivity, anxiety, tension, and183
nervousness. Between 1990 and 1997, the FDA reported that 160 deaths and 569
hospitalizations were associated with children taking Ritalin,184 yet the drug remains on
the market. For more recent examples, recall the withdrawal of Vioxx from the market
in the fall of 2004185 and the warnings issued about other non-steroid anti-inflammatory
drugs, such as Bextra and Celebrex. 186 Furthermore, many other FDA-approved drugs
177. See id.
178. See discussion supra Part lI.B.
179. See discussion supra Part IV.B.
180. See Dietary Supplements: Hearing Before the Senate Comm. on Commerce, Science, &
Transportation, 108th Cong. (2003) (testimony of David Seckman, executive director, NNFA), available at
http://commerce.senate.gov/hearings/testimony.cfm?id=976&witid=2748 (last visited Mar. 15, 2005)
[hereinafter Testimony of Seckman].
181. See Joshua H. Beisler, Note, Dietary Supplements and Their Discontents: FDA Regulation and the
Dietary Supplement Health and Education Act of 1994, 31 RUTGERs L.J. 511, 512 (2000); see also Statement
of Sen. Hatch, supra note 172.
182. Testimony of Seckman, supra note 180.
183. Hazel L. White, Ritalin Update for Counselors, Teachers, and Parents, 124 EDUC. 289, 293 (2003).
The drug is commonly known as Ritalin. See Nat'l Inst. On Drug Abuse, NIDA InfoFacts: Methylphenidate
(Ritalin), at http://www.nida.nih.gov/Infofax/ritalin.html (last visited Apr. 2, 2005).
184. O'Meara, supra note 169.
185. Merck & Co., the manufacturer of the non-steroid anti-inflammatory drug, voluntarily withdrew
Vioxx from the market in September 2004 after a safety-monitoring board overseeing a long-term study of the
drug recommended that the study be halted because of an increased risk of serious cardiovascular events,
including heart attacks and strokes. Press Release, U.S. Food and Drug Admin., FDA Issues Public Health
Advisory on Vioxx as its Manufacturer Voluntarily Withdraws the Product (Sept. 30, 2004), available at
http://www.fda.gov/bbs/topics/news/2004/NEW01122.html (last visited Mar. 15, 2005).
186. In December 2004, the FDA issued a public health advisory alerting consumers of potential dangers
of using products such as Bextra and Celebrex-known as COX-2 selective agents-because of the increased
risk of serious cardiovascular events such as heart attacks and strokes. Press Release, U.S. Food and Drug
Admin., FDA Issues Public Health Advisory Recommending Limited Use of Cox-2 Inhibitors: Agency
Requires Evaluation of Prevention Studies Involving Cox-2 Selective Agents (Dec. 23, 2004), available at
http://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01336.html (last visited Mar. 15, 2005).
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ranging from Prozac, which is used for the treatment of depression, to Accutane, which
is used for treating acne, have had serious adverse reactions reported against them.
187
In contrast, the FDA has received a small number of reports of adverse events
associated with the consumption of dietary supplements. For example, the FDA
received a mere 1,214 reports of adverse events regarding all dietary supplements in
2001, which includes reports of injuries with varying levels of seriousness.188 Thus,
even if the FDA does approve the product, whether it is a prescription drug or a dietary
supplement, adverse reactions to the products may still occur. A requirement that the
dietary supplement receives FDA premarket approval will therefore not ensure the
safety of the supplement.
Essentially, the Dietary Supplement Safety Act would grant the FDA
unprecedented-and nearly unlimited-power to remove dietary supplements from the
market, and many dietary supplements that consumers have enjoyed taking for many
years without experiencing any harmful side effects could suddenly be banned. As
Julian Whitaker, a medical doctor who founded the Whitaker Wellness Institute in
California, stated, "[T]his legislation isn't about safety at all. It's about loss of control
that the FDA has experienced ...when it comes to regulation of the nutritional-
supplement industry with the passage of the [DSHEA]."' 189 This proposed legislation is
not the appropriate solution for ensuring that consumers are safe from dangers that
dietary supplements such as ephedra may pose.
2. The Better Solution: DSHEA Full Implementation and Enforcement Act of 2003
Several months after Sen. Durbin introduced the Dietary Supplement Safety Act,
Sen. Tom Harkin (D-Iowa), along with Sen. Hatch, introduced the DSHEA Full
Implementation and Enforcement Act of 2003 ("DSHEA Full Implementation and
Enforcement Act"), 190 which offers a different, and more sensible, approach to
addressing the problems of dietary supplements than Sen. Durbin's approach.
The DSHEA Full Implementation and Enforcement Act's stated purpose is to
"ensure that the goals of the [DSHEA] are met by authorizing appropriations to fully
enforce and implement" the DSHEA. 19 1 In contrast to Sen. Durbin's drastic and unduly
restrictive proposal, which essentially requires a rewriting of the DSHEA, Sen. Harkin's
approach would provide the FDA with sufficient resources to be able to implement the
current law.192 For example, the bill would give the FDA $20 million beginning in the
fiscal year ("FY") 2004193 and an increasing amount each proceeding year until FY
187. See id.; see also Letter from Janet Woodcock, Director, Ctr. for Drug Evaluation and Research, to
Consumers (Jan. 9, 2001), at http://www.fda.gov/cder/drug/infopage/accutane/accutane-ltr.htm (last visited
Mar. 15, 2005) (indicating that Accutane, while effective for treating acne, is known to cause a range of birth
defects).
188. Testimony of David Seckman, supra note 180.
189. O'Meara, supra note 169.
190. S. 1538, 108th Cong. (2003). The DSHEA Full Implementation and Enforcement Act of 2003 is a
proposed bill separate to Hatch's proposed amendment to the DOD Authorization Bill.
191. Id.
192. Id. § 3.
193. Id. § 3(a)(1).
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2008.194 The bill also gives funds to ODS for expanded research and development of
consumer information on dietary supplements. 1
95
According to this bill, the DSHEA would remain the controlling law, but the FDA
would receive more resources in order to investigate adverse event reports associated
with dietary supplements. One major problem with the DSHEA is the difficulty in
enforcing it; the FDA simply does not have the funds to adequately respond to the
adverse reports that it receives. 196  Sen. Harkin's proposal, however, offers a good
solution by appropriating sufficient funds to the FDA to effectively enforce the law. As
Sen. Hatch has stated, "[T]he FDA must use [the DSHEA] for it to be effective, and
Congress must support the agency in that effort."' 197 If the FDA had more funds, the
agency could conduct more detailed investigations into dietary supplements that harm a
large number of people. 198 At the same time, Sen. Harkin's proposal keeps the current
law in place so that consumers are ensured access to affordable alternative medicines.
3. Sen. Durbin's Second Attempt: Amendment 3225
In conjunction with his proposed Dietary Supplement Safety Act, Sen. Durbin
made a second attempt to increase the regulation of dietary supplements by offering
another proposal in May 2004. The proposal, outlined in Amendment 3225 to the
National Defense Authorization Act for Fiscal Year 2005 ("DOD Authorization
Bill"),'" would have required manufacturers who sell dietary supplements containing
stimulants on military installations to turn over to the FDA any serious adverse event
reports relating to the products. 20 Thus, the amendment would have restricted access
to dietary supplements containing caffeine as an ingredient and drinks containing
stimulants on military bases and implemented a mandatory reporting scheme from
manufacturers of dietary supplements sold on military bases to the FDA.20 1  As
justification for the amendment, Durbin stated, "Military personnel are under unusual
pressure to be physically fit, making dietary supplements particularly attractive ....
Soldiers face enough danger in the field. They shouldn't have to worry about purported
health products that are sold at military commissaries, but not monitored for safety."
' 20 2
Sen. Durbin's proposal received heavy criticism, particularly from Sen. Hatch, who
has been an outspoken critic of increased regulation of the dietary supplement industry.
Stating that the proposal was "a solution in search of a problem,"'203  Sen. Hatch
194. Id. § 3 (a)(l)-(5).
195. Id. § 3(c).
196. See Statement of Sen. Hatch, supra note 161.
197. See id.
198. Id.
199. S. 2400 amend. 3225, 108th Cong. (2004).
200. Press Release, U.S. Senator of Illinois Dick Durbin, Durbin Amendment to Report Serious Health
Effects of Dietary Supplements Debated Today by Senate (June 18, 2004), available at
http://durbin.senate.gov/-durbin/new200l/press/2004/06/2004630454.html (last visited Apr. 2, 2005)
[hereinafter Durbin Press Release].
201. See id. However, "[a]n exemption is provided for beverages containing caffeine, such as tea, coffee
and sports drinks." Id. See also Sens Hatch, Harkin and Durbin Pledge Mandatory Supps' AE Reporting
Legislation, NEUTRACEUTICALS INT'L, July 1, 2004, available at 2004 WL 86975163 [hereinafter Pledge].
202. Durbin Press Release, supra note 200.
203. Press Release, Sen. Orrin Hatch, Statement: Dietary Supplement Amendments to the DOD
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opposed Amendment 3225 for three primary reasons. First, Hatch highlighted the
inconsistency in singling out military personnel when the issue is of national concern
and does not just concern military installations. 204  Second, Hatch objected to the
separation of those dietary supplements containing stimulants from other dietary
supplements.205 Third, Hatch said that the timing of this amendment was "premature,"
as no agency, including the FDA, has taken a position regarding the issue Sen. Durbin
proposed in his amendment. 206  Moreover, Hatch cautioned against using the DOD
Authorization Bill as the place to work through issues involving the regulation of
dietary supplements as the serious shortcomings of the existing adverse event reporting
system should be reformed before a mandatory reporting system is implemented.
20 7
In response to Sen. Durbin's proposed amendment, Sen. Hatch, along with Sen.
Harkin, presented an alternative amendment to the DOD Authorization Bill,
Amendment 3463.208 Amendment 3463 proposed the following: (1) to require the
FDA to make it a priority to "fully and effectively" implement the DSHEA, including
taking appropriate enforcement action against unsafe dietary supplements; (2) to require
HHS to develop a plan for mandatory reporting of serious adverse events resulting from
taking dietary supplements; and (3) to increase the resources and funding available to
the FDA for overseeing dietary supplements and for scientific research on the effects of
dietary supplements.
20 9
Following the introduction of Amendment 3463, Sen. Durbin responded to the
criticism against his proposed amendment by agreeing to collaborate with Sen. Hatch
and Sen. Harkin to develop a comprehensive law to address the FDA's inability to
respond effectively to adverse event reports. 2 1 In agreeing to work together to reach a
solution, the senators agreed to withdraw their proposed amendments to the DOD
Authorization Bill.
211
The senators made no significant progression towards achieving this agreement
until a federal district court in Utah issued its ruling in Neutraceutical Corp. v.
Crawford.212 Immediately following the release of this decision, Sen. Hatch and Sen.
Durbin met to discuss the introduction of a reporting bill that likely would give the FDA
authority to mandate adverse event reporting.21 3 FDA Week reports that the bill may
require the manufacturer, distributor, or retailer of a dietary supplement to report
adverse events to the FDA and would hold these same actors responsible for the
Authorization Bill (June 21, 2004), available at http://hatch.senate.gov/index.cfin?FuseAction=Press
Releases.View&PressReleaseid=1081 (last visited Feb. 10, 2005) [hereinafter Press Release, Statement:
Dietary Supplement Amendment].
204. Id.
205. Id.
206. Id.
207. Id.; see also Pledge, supra note 201.
208. 150 CONG. REC. S7062-02 (daily ed. June 21, 2004) (statement of Sen. Hatch).
209. Id.
210. Id. (statements of Sen. Hatch and Sen. Durbin); see also discussion supra Part.ll.B.
211. 150 Cong. Rec. S7062-02 (statements of Sen. Hatch and Sen. Durbin).
212. Hatch Pushes Bill Mandating Supplement Adverse Event Reports, FDA WEEK, Apr. 15, 20005, at
2005 WLNR 5893100 [hereinafter Hatch Pushes Bill]; Neutraceutical Corp., 2005 WL 852157, at *10. See
also discussion supra Part.llI.C.
213. Hatch Pushes Bill, supra note 212.
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214accuracy and completeness of the adverse event reports. However, to date, neither
senator has released an official version of the bill.
4. Institute of Medicine Panel Calls for Higher Standards
In addition to the flurry of legislative action directed toward changes in the dietary
supplement law, a private organization backed by the federal government has
contributed to the controversial issue. In early January 2005, a panel convened by the
IOM, 2 15 at the bequest of NCCAM, released a report urging Congress to revise the
DSHEA to heighten the regulation standards for dietary supplements.
216
Expressing concern over the reliability of dietary supplements, the panel called for
stronger quality controls on dietary supplements, including a requirement that dietary
supplements be held to the same clinical standards as drugs.2 17 Dr. David Eisenberg,
director of research into complementary therapies at Harvard Medical School and a
member of the panel, said that the panel was most concerned about quality because
"you can't be assured from batch to batch" that the products are reliable. 2 18
Furthermore, Dr. Stephen E. Straus, director of NCCAM, said that requiring the same
research standards for dietary supplements and drugs would "further the scientific
investigation of this new field, increase its legitimacy as a research area and ultimately
improve public health."2 19  In addition to the recommendations for stronger quality
controls, the panel called for the DSHEA to improve standards for label accuracy and to
institute stronger enforcement against false and misleading claims of adverse events
associated with dietary supplements.
220
Unsurprisingly, Sen. Durbin praises the IOM's report as further proof that the
DSHEA should be changed, 2 2 1 and he will undoubtedly use this report as fuel to
continue his push for Congress to adopt his proposed Dietary Supplement Safety Act.
Equally predictable, the dietary supplement industry is criticizing the IOM report,
blasting the panel for being misinformed about the DSHEA and about dietary
supplements in general. 2 2 2  For example, the Council for Responsible Nutrition
("CRN") 223 called the IOM report "an unwarranted hatchet job" that "focuse[d] ...
entirely on repeating a few shopworn criticisms with little attention to the positive
science underlying the safety and benefits of a wide variety of products and no attention
214. See id.
215. The Institute of Medicine is part of the National Academy of Science, a private organization created
by Congress to advise the government on scientific and technical matters.
216. IOM: Revise DSHEA, Hold Supplements to Drug Research Standards, FDA WEEK, Jan. 14, 2005
[hereinafter IOM: Revise DSHEA].
217. Id.
218. Delthia Ricks, Panel: Treat Them Like Drugs; Experts Conclude that Diet Supplements, Alternative
Medicine Should Be Subject to Tougher Regulations, NEWSDAY, Jan. 13, 2005, at A28.
219. Complementary; Alternative Medicine; Panel Wants Tougher Supplement Standards, MED. LETTER
ON THE CDC & FDA, Feb. 6, 2005, at 2005 WL 55339773.
220. 1OM: Revise DSHEA, supra note 216.
221. Id.
222. Id.
223. The Council for Responsible Nutrition is a trade association representing ingredient suppliers and
manufacturers in the dietary supplement industry. Council for Responsible Nutrition, About CRN, at
http://www.crnusa.org/who-about.html (last visited Mar. 15, 2005).
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... to the outstanding quality assurance and manufacturing controls that are typical of
leading companies in the industry."' 224  Furthermore, CRN criticizes the report's
recommendation to hold dietary supplements to the same standards as drugs since
dietary supplements have always been classified as food and have never been
considered drugs.225 Finally, CRN argues that, instead of amending the DSHEA as the
report suggests, the more appropriate action is for the FDA to continue its goal of
improving enforcement of the DSHEA and of finalizing the cGMP rule that it has set
forth to complete.
226
Although the consequences of this report are yet to be realized, the report
highlights the line drawn between those calling for stronger regulation of dietary
supplements and those advocating for better enforcement of the law already in place.
The DSHEA is adequate to deal with the problems surrounding dietary supplements and
should not be amended; however, increased enforcement of the DSHEA is necessary.
E. The Ban on Ephedra Shows that the DSHEA Works
The FDA proved that the DSHEA does indeed work when it banned ephedra in
December 2003. The FDA has the ability to exercise its power, authorized under the
DSHEA, to ban a dietary supplement determined to present a significant risk to
consumer health. Ephedra presented such a risk, and the FDA was successful in
removing it from the market. Instead of threatening the safety of consumers, the
DSHEA ensures consumers that they may have access to dietary supplements and do
not have to rely solely on prescription drugs to relieve their ailments.
When Congress passed the DSHEA, it found "a link between the ingestion of
certain nutrients or dietary supplements and the prevention of chronic diseases such as
cancer, heart disease, and osteoporosis"227 and that "healthful diets may mitigate the
need for expensive medical procedures, such as coronary bypass surgery or angioplasty
.... ,228 Congress further relied on "national surveys [that] have revealed that almost
50 percent of the 260,000,000 Americans regularly consume dietary supplements of
vitamins, minerals, or herbs as a means of improving their nutrition"'229 as support for
passing the DSHEA. Congress recognized that consumers demand, need, and are
entitled to use dietary supplements to improve their health.
The DSHEA does give the FDA authority to pull dangerous supplements off the
shelves and to warn consumers against using certain products, as proved with the ban
224. Press Release, Council for Responsible Nutrition, CRN Calls IOM Report on Complementary and
Alternative Medicine an "Unwarranted Hatchet Job on Supplements" (Jan. 12, 2005), available at
http://www.cmusa.org/PR05_0112_IOMCAM.html (last visited Mar. 15, 2005) [hereinafter Press Release,
CRN Calls IOM Report].
225. Id. (Annette Dickenson, CRN President, states, "Dietary supplements are not drugs, have never been
drugs, and will never rightly be considered drugs. Congress has carefully reviewed the food/drug issue on
three separate occasions in the last 65 years and has come down on the food side every time."); see also
discussion supra Part II.A (addressing dietary supplements being regulated as food additives and not drugs
under the FDCA).
226. Press Release, CRN Calls IOM Report, supra note 224; see also discussion supra Part.I.B.
227. Dietary Supplement Health and Education Act of 1994, Pub. L. No. 103-417, § 2(3)(A), 108 Stat.
4325 (1994).
228. Id. § 2(4).
229. Id. § 2(9).
2005]
Journal of Legislation
on ephedra. 23  Furthermore, when andro appeared to endanger as many people and
attracted the same level of media attention as ephedra, the FDA took action to ban that
supplement from the market as well.2 3 1 Although the FDA used the wrong method and
analysis in effectively removing andro from the market, 232 the fact that the FDA reacted
to the dangers presented by andro indicates that the FDA will react again should another
supplement present such dangers in the future. Until a supplement presents such
dangers, however, the FDA should continue to evaluate the dietary supplements on a
case-by-case basis, as provided for in the DSHEA.
If the FDA is granted expansive authority to regulate these dietary supplements, as
Sen. Durbin and the IOM report propose, consumers will suffer. Therefore, the
DSHEA should remain as originally enacted, but with the additional appropriations that
Sen. Harkin proposes in the DSHEA Full Implementation and Enforcement Act.233 If
the FDA had more funding to investigate dietary supplements, and if other
organizations, such as ODS, had more money to conduct research on the health benefits
and risks of taking dietary supplements, then consumers would be able to experience the
best of both worlds-they would be able to continue to have access to the herbal
remedies that provide affordable treatments for their ailments, and they would receive
better information regarding the side effects associated with dietary supplements.
F. The FDA Should Do More to Educate Consumers about Dietary Supplements
Instead of changing the DSHEA, as Sen. Durbin proposes, the federal government
should ensure that consumers receive more information about the safety of dietary
supplements. Instead of taking away consumer access to dietary supplements by
banning them or making it more difficult for supplement manufacturers to market their
products, the FDA should arm consumers with knowledge about the effects of the major
dietary supplements so consumers can make informed decisions about which
supplements to use.
The FDA can take several actions to accomplish this task. For example, the FDA
and ODS could use a portion of the money that Sen. Harkin provides in his proposed
bill to create consumer information pamphlets about the potential dangers of using
dietary supplements. The FDA should recommend that every grocery store and natural
foods store create a display, using these pamphlets, in the dietary supplement aisle so
that consumers would have easy access to this information. The FDA should also
provide a consumer-friendly website that includes a statistical analysis of the number of
adverse event reports associated with each dietary supplement. The website could also
contain basic background information on the major dietary supplements and tips for
consumers on how often and in what dosage to take the supplement. Finally, the FDA
should launch a nationwide advertising campaign to educate consumers about the issues
and potential dangers of using dietary supplements. The campaign should include
230. See discussion supra Part II.B.
231. See discussion supra Part.IV.A.
232. See id.
233. See discussion supra Part IV.B.2.
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creating television commercials and advertisement placements in health and general
consumer magazines and newspapers.
Solutions such as these will not ensure that consumers will experience no adverse
effects associated with dietary supplements, but consumers will at least be able to make
informed choices about which dietary supplements to purchase and take. Consumers
will no longer believe that the products are harm-free and may proceed in using them
with more caution.
V. CONCLUSION
Ephedra is only one dietary supplement that has had serious adverse effects amidst
many more that have helped consumers improve their health and well-being. The fact
that consumers voiced such strong opposition to the FDA's attempt to heavily regulate
the dietary supplement industry that Congress had to react shows that consumers
want-and demand-access to herbal supplements. The FDA made a bold move in
December 2003 by banning a dietary supplement for the first time, and while that move
was indeed a necessary and timely reaction to the dangers that ephedra posed to public
health and safety, the FDA should not use it as ammunition to launch an attack against
the dietary supplement industry.
Consumers will be hurt if the FDA begins to ban more and more dietary
supplements, even if some consumers have experienced adverse reactions. Just as
prescription drugs, despite all the testing that they undergo, cause some people to
experience side effects when taking them, the same may occur with dietary
supplements. However, consumers should still be entitled to access those dietary
supplements and choose, for themselves, what types of remedies may suit them best.
The DSHEA is in place to ensure that consumers do, in fact, have access to dietary
supplements, and the legislation must remain to prevent the FDA from stripping these
herbal remedies from the public.
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